# A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

> **NCT03273153** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 446 (actual)

## Conditions studied

- Advanced BRAFV600 Wild-type Melanoma

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Atezolizumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03273153
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-11
- **Primary completion:** 2019-04-15
- **Final completion:** 2021-02-19
- **Target enrollment:** 446 (ACTUAL)
- **Why stopped:** This study was terminated due to benefit/risk analysis.
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03273153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03273153, "A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03273153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*